Microneedle technology could help simplify vaccine delivery to better support global immunization efforts, and Australia is leading the way in this innovative technology.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akeso, Avadel, Formycon, Hutchmed, Innovent, Sydnexis, Telix, Tempest, Vigeneron.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alvotech, Basilea, Casma, Cullinan, Dr. Reddy’s, Genrix, Harmony, Immunoprecise, Lupin, Neurop, Ocugen, Pincell, Pfizer, Scinai, Seyltx.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Corcept, Duality, Immunic, Maia, Novartis, Regenxbio.
Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma companies raised $5.55 billion in May, more than doubling the $2.4 billion raised in April.
As it advances its nonopioid analgesic ATX-101 breakthrough therapy through a phase IIb registration trial, Allay Therapeutics secured $57.5 million in a series D round, which included an investment from the company’s Japanese partner. ATX-101, a configuration of sodium ion channel blocker bupivacaine and a biopolymer, which is in a phase IIb registration study, is designed to offer pain relief following total knee arthroplasty.
RSS
